Phathom Pharmaceuticals annual total debt
2018
2019
2020
2021
2022
2023
2024
2025
Phathom Pharmaceuticals Total Debt Growth & History (PHAT)
Phathom Pharmaceuticals's total debt was $211.8M for fiscal 2025.
View full Phathom Pharmaceuticals company overviewPhathom Pharmaceuticals annual total debt history
| Fiscal year | Period ended | Total debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $211.8M | $9.9M | +4.90% |
| 2024 | 2024-12-31 | $201.9M | $62.9M | +45.23% |
| 2023 | 2023-12-31 | $139.0M | $42.0M | +43.23% |
| 2022 | 2022-12-31 | $97.1M | $5.7M | +6.27% |
| 2021 | 2021-12-31 | $91.3M | $42.3M | +86.34% |
| 2020 | 2020-12-31 | $49.0M | $25.4M | +107.94% |
| 2019 | 2019-12-31 | $23.6M | $21.6M | +1108.87% |
| 2018 | 2018-12-31 | $1.9M | — | — |
Phathom Pharmaceuticals quarterly total debt
Q4.18
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $167.1M | −$38.9M | −18.86% |
| Q1 2026 | 2026-03-31 | $166.3M | −$37.3M | −18.30% |
| Q4 2025 | 2025-12-31 | $211.8M | $9.9M | +4.90% |
| Q3 2025 | 2025-09-30 | $209.8M | $33.4M | +18.93% |
| Q2 2025 | 2025-06-30 | $206.0M | $30.7M | +17.51% |
| Q1 2025 | 2025-03-31 | $203.6M | $53.5M | +35.67% |
| Q4 2024 | 2024-12-31 | $201.9M | $62.9M | +45.23% |
| Q3 2024 | 2024-09-30 | $176.4M | $75.8M | +75.34% |
| Q2 2024 | 2024-06-30 | $175.3M | $76.0M | +76.49% |
| Q1 2024 | 2024-03-31 | $150.0M | $51.8M | +52.65% |
| Q4 2023 | 2023-12-31 | $139.0M | $42.0M | +43.23% |
| Q3 2023 | 2023-09-30 | $100.6M | $4.8M | +5.01% |
| Q2 2023 | 2023-06-30 | $99.3M | $4.9M | +5.15% |
| Q1 2023 | 2023-03-31 | $98.3M | $5.7M | +6.14% |
| Q4 2022 | 2022-12-31 | $97.1M | $5.7M | +6.27% |
| Q3 2022 | 2022-09-30 | $95.8M | $5.7M | +6.37% |
| Q2 2022 | 2022-06-30 | $94.5M | $44.9M | +90.66% |
| Q1 2022 | 2022-03-31 | $92.6M | $43.3M | +87.87% |
| Q4 2021 | 2021-12-31 | $91.3M | $42.3M | +86.34% |
| Q3 2021 | 2021-09-30 | $90.1M | $41.4M | +84.97% |
| Q2 2021 | 2021-06-30 | $49.5M | $1.1M | +2.31% |
| Q1 2021 | 2021-03-31 | $49.3M | $2.6M | +5.63% |
| Q4 2020 | 2020-12-31 | $49.0M | $25.4M | +107.94% |
| Q3 2020 | 2020-09-30 | $48.7M | $26.1M | +115.35% |
| Q2 2020 | 2020-06-30 | $48.4M | — | — |
| Q1 2020 | 2020-03-31 | $46.7M | — | — |
| Q4 2019 | 2019-12-31 | $23.6M | $21.6M | +1108.87% |
| Q3 2019 | 2019-09-30 | $22.6M | — | — |
| Q4 2018 | 2018-12-31 | $1.9M | — | — |
Phathom Pharmaceuticals total debt trends
Over the last five fiscal years, Phathom Pharmaceuticals's total debt increased from $49.0M to $211.8M, a change of $162.8M. The latest reported quarter, Q2 2026, shows $167.1M.
About the metric
What total debt means
Total debt measures a company’s reported interest-bearing borrowing obligations at a reporting-period end. It can include short-term borrowings, current maturities, long-term debt, and finance lease obligations when they are included in the company’s debt facts.
Calculation and source
SEC-reported and combined total debt
TickerStat uses a reported aggregate debt value when available. Otherwise, it combines non-overlapping current and noncurrent debt facts from SEC filings. Total liabilities are not treated as debt, and missing debt is not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Phathom Pharmaceuticals source filings ↗Community posts
Phathom’s Voquezna growth narrows its quarterly loss and supports positive operating cash flow
Phathom Pharmaceuticals ($PHAT) reported third-quarter 2026 revenue of $84.7 million, up 71% from a year earlier and 14% from the preceding quarter. Cumulative Voquezna prescriptions surpassed two million, reflecting continued adoption of t ...
Phathom’s Voquezna exclusivity dispute expands with FDA consultation and another challenger
Phathom ($PHAT) said the FDA opened a public docket seeking comment on legal and regulatory questions raised by a challenge to Voquezna’s exclusivity. Comments are due by November 23. Phathom has also moved to intervene in BDR Pharmaceutica ...
